Mechanisms and Efficacy of Chinese Herbal Medicines in Chronic Kidney Disease

Overview

Journal Front Pharmacol

Date 2021 Apr 15

PMID 33854427

Citations 10

Authors

Mingming Zhao

Yi Yu

Rumeng Wang

Meiying Chang

Sijia Ma

Hua Qu

Yu Zhang

Affiliations

Soon will be listed here.

Abstract

As the current treatment of chronic kidney disease (CKD) is limited, it is necessary to seek more effective and safer treatment methods, such as Chinese herbal medicines (CHMs). In order to clarify the modern theoretical basis and molecular mechanisms of CHMs, we reviewed the knowledge based on publications in peer-reviewed English-language journals, focusing on the anti-inflammatory, antioxidative, anti-apoptotic, autophagy-mediated and antifibrotic effects of CHMs commonly used in kidney disease. We also discussed recently published clinical trials and meta-analyses in this field. Based on recent studies regarding the mechanisms of kidney disease and , CHMs have anti-inflammatory, antioxidative, anti-apoptotic, autophagy-mediated, and antifibrotic effects. Several well-designed randomized controlled trials (RCTs) and meta-analyses demonstrated that the use of CHMs as an adjuvant to conventional medicines may benefit patients with CKD. Unknown active ingredients, low quality and small sample sizes of some clinical trials, and the safety of CHMs have restricted the development of CHMs. CHMs is a potential method in the treatment of CKD. Further study on the mechanism and well-conducted RCTs are urgently needed to evaluate the efficacy and safety of CHMs.

Citing Articles

Design and screening of novel molecular compounds targeting lactate dehydrogenase of Babesia microti.

Luo W, Yu L, Lu S, Yu Y, Bai Y, Wang S Parasit Vectors. 2025; 18(1):69.

PMID: 39988659 PMC: 11847361. DOI: 10.1186/s13071-024-06623-9.

Shenshuaikang enema restores the intestinal barrier and microbiota-gut-kidney axis balance to alleviate chronic kidney disease via NF-κB pathway.

Ye Y, Huang X, Li X, Gao F, Zhong W, Tang A Front Pharmacol. 2025; 15:1453668.

PMID: 39906395 PMC: 11790348. DOI: 10.3389/fphar.2024.1453668.

Network pharmacology and multi-omics validation of the Jianpi-Yishen formula in the treatment of chronic kidney disease.

Li Y, Luo Y, Hu Y, Li S, Li G, Zhang W Front Immunol. 2025; 15:1512519.

PMID: 39877349 PMC: 11772200. DOI: 10.3389/fimmu.2024.1512519.

Exploring the prevalence of gout among underrepresented low socioeconomic status type 2 diabetes populations.

Smith J, Martin A, Mundadan J, Roberts M, Roman Y, Bravo-Nuevo A Diabetol Metab Syndr. 2025; 17(1):25.

PMID: 39833933 PMC: 11748529. DOI: 10.1186/s13098-025-01586-y.

Metabolic reprogramming and renal fibrosis: what role might Chinese medicine play?.

Wang W, Dai R, Cheng M, Chen Y, Gao Y, Hong X Chin Med. 2024; 19(1):148.

PMID: 39465434 PMC: 11514863. DOI: 10.1186/s13020-024-01004-x.

References

Wang Y, He L, Sun W, Lu Y, Wang X, Zhang P . Optimized project of traditional Chinese medicine in treating chronic kidney disease stage 3: a multicenter double-blinded randomized controlled trial. J Ethnopharmacol. 2011; 139(3):757-64. DOI: 10.1016/j.jep.2011.12.009. View

Su J, Zhang P, Zhang J, Qi X, Wu Y, Shen J . Effects of total glucosides of paeony on oxidative stress in the kidney from diabetic rats. Phytomedicine. 2009; 17(3-4):254-60. DOI: 10.1016/j.phymed.2009.07.005. View

Yang C, Guo Y, Huang T, Zhao J, Huang X, Tang H . Asiatic acid protects against cisplatin-induced acute kidney injury via anti-apoptosis and anti-inflammation. Biomed Pharmacother. 2018; 107:1354-1362. DOI: 10.1016/j.biopha.2018.08.126. View

Zhang B, Zhang X, Zhang C, Shen Q, Sun G, Sun X . Notoginsenoside R1 Protects db/db Mice against Diabetic Nephropathy via Upregulation of Nrf2-Mediated HO-1 Expression. Molecules. 2019; 24(2). PMC: 6359411. DOI: 10.3390/molecules24020247. View

Zhang Y, Tan R, Zhang X, Yu Y, Yu C . Calycosin Ameliorates Diabetes-Induced Renal Inflammation via the NF-κB Pathway In Vitro and In Vivo. Med Sci Monit. 2019; 25:1671-1678. PMC: 6413560. DOI: 10.12659/MSM.915242. View

Kaushal G, Chandrashekar K, Juncos L . Molecular Interactions Between Reactive Oxygen Species and Autophagy in Kidney Disease. Int J Mol Sci. 2019; 20(15). PMC: 6696055. DOI: 10.3390/ijms20153791. View

Zhang M, Feng L, Zhu M, Gu J, Jiang J, Cheng X . The anti-inflammation effect of Moutan Cortex on advanced glycation end products-induced rat mesangial cells dysfunction and High-glucose-fat diet and streptozotocin-induced diabetic nephropathy rats. J Ethnopharmacol. 2013; 151(1):591-600. DOI: 10.1016/j.jep.2013.11.015. View

Wang X, Gao Y, Tian N, Wang T, Shi Y, Xu J . Astragaloside IV inhibits glucose-induced epithelial-mesenchymal transition of podocytes through autophagy enhancement via the SIRT-NF-κB p65 axis. Sci Rep. 2019; 9(1):323. PMC: 6344540. DOI: 10.1038/s41598-018-36911-1. View

Ju Y, Su Y, Chen Q, Ma K, Ji T, Wang Z . Protective effects of Astragaloside IV on endoplasmic reticulum stress-induced renal tubular epithelial cells apoptosis in type 2 diabetic nephropathy rats. Biomed Pharmacother. 2018; 109:84-92. DOI: 10.1016/j.biopha.2018.10.041. View

10.

Liang S, Bi J, Guo Z, Bai Y, Hu Z . Protective effect of icariin on kidney in 5/6 nephrectomized rats and its mechanism. Genet Mol Res. 2014; 13(3):6466-71. DOI: 10.4238/2014.August.25.10. View

11.

Xu G, Luo K, Liu H, Huang T, Fang X, Tu W . The progress of inflammation and oxidative stress in patients with chronic kidney disease. Ren Fail. 2014; 37(1):45-9. DOI: 10.3109/0886022X.2014.964141. View

12.

Hou B, Qiang G, Zhao Y, Yang X, Chen X, Yan Y . Salvianolic Acid A Protects Against Diabetic Nephropathy through Ameliorating Glomerular Endothelial Dysfunction via Inhibiting AGE-RAGE Signaling. Cell Physiol Biochem. 2017; 44(6):2378-2394. DOI: 10.1159/000486154. View

13.

Li P, Chen Y, Liu J, Hong J, Deng Y, Yang F . Efficacy and safety of tangshen formula on patients with type 2 diabetic kidney disease: a multicenter double-blinded randomized placebo-controlled trial. PLoS One. 2015; 10(5):e0126027. PMC: 4418676. DOI: 10.1371/journal.pone.0126027. View

14.

Wei Q, Dong G, Chen J, Ramesh G, Dong Z . Bax and Bak have critical roles in ischemic acute kidney injury in global and proximal tubule-specific knockout mouse models. Kidney Int. 2013; 84(1):138-48. PMC: 3686831. DOI: 10.1038/ki.2013.68. View

15.

Li Z, Zhang W . Protective effect of berberine on renal fibrosis caused by diabetic nephropathy. Mol Med Rep. 2017; 16(2):1055-1062. PMC: 5562073. DOI: 10.3892/mmr.2017.6707. View

16.

Chen Y, Deng Y, Ni Z, Chen N, Chen X, Shi W . Efficacy and safety of traditional chinese medicine (Shenqi particle) for patients with idiopathic membranous nephropathy: a multicenter randomized controlled clinical trial. Am J Kidney Dis. 2013; 62(6):1068-76. DOI: 10.1053/j.ajkd.2013.05.005. View

17.

Matsushita K, van der Velde M, Astor B, Woodward M, Levey A, de Jong P . Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010; 375(9731):2073-81. PMC: 3993088. DOI: 10.1016/S0140-6736(10)60674-5. View

18.

Ji C, Luo Y, Zou C, Huang L, Tian R, Lu Z . Effect of astragaloside IV on indoxyl sulfate-induced kidney injury in mice via attenuation of oxidative stress. BMC Pharmacol Toxicol. 2018; 19(1):53. PMC: 6122638. DOI: 10.1186/s40360-018-0241-2. View

19.

Tripathi Y, Shukla R, Pandey N, Pandey V, Kumar M . An extract of Pueraria tuberosa tubers attenuates diabetic nephropathy by upregulating matrix metalloproteinase-9 expression in the kidney of diabetic rats. J Diabetes. 2016; 9(2):123-132. DOI: 10.1111/1753-0407.12393. View

20.

Ru Y, Luo Y, Zhou Y, Kuai L, Sun X, Xing M . Adverse Events Associated With Treatment of Hook F: A Quantitative Evidence Synthesis. Front Pharmacol. 2019; 10:1250. PMC: 6851843. DOI: 10.3389/fphar.2019.01250. View